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Highlights 
 Metabolites in faecal extracts were profiled using nanospray-nanoscale LC-MS 
 nUHPLC-nESI-TOFMS analyses gave repeatable peak retention times and intensities 
 A pilot metabolomics study revealed differences between CRC and healthy patients  
 Signalling metabolites were some key classes discriminating between patient groups 
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1.0 Abstract 
Faeces are comprised of a wide array of metabolites arising from the circulatory system as well as the 
human microbiome. A global metabolite analysis (metabolomics) of faecal extracts offers the potential 
to uncover new compounds which may be indicative of the onset of bowel diseases such as colorectal 
cancer (CRC). To date, faecal metabolomics is still in its infancy and the compounds of low abundance 
present in faecal extracts poorly characterised. In this study, extracts of faeces from healthy subjects 
were profiled using a sensitive nanoflow-nanospray LC-MS platform which resulted in highly 
repeatable peak retention times (<2% CV) and intensities (<15% CV). Analysis of the extracts revealed 
wide coverage of the faecal metabolome including detection of low abundant signalling compounds 
such as sex steroids and eicosanoids, alongside highly abundant pharmaceuticals and tetrapyrrole 
metabolites. A small pilot study investigating differences in metabolomics profiles of faecal samples 
obtained from 7 CRC, 25 adenomatous polyp and 26 healthy groups revealed that secondary bile acids, 
conjugated androgens, eicosanoids, phospholipids and an unidentified haem metabolite were 
potential classes of metabolites that discriminated between the CRC and control sample groups. 
However, much larger follow up studies are needed to confirm which components of the faecal 
metabolome are associated with actual CRC disease rather than dietary influences. This study reveals 
the potential of nanospray-nanoflow LC-MS profiling of faecal samples from large scale cohort studies 
for uncovering the role of the faecal metabolome in colorectal disease formation. 
 
Key words: metabolomics; nanoLC; nanoESI; Colon cancer, LC-MS; Faeces; 
 
 
2.0 Introduction 
The use of metabolomic analysis for the discovery of early markers of disease has been 
successfully achieved using matrices such as urine [1], plasma/serum [2], cerebrospinal fluid [3] and 
saliva.[4] However, faecal metabolomics is still very much in its infancy despite offering huge potential 
for biomarker discovery for diseases of the gut. [5] [6] To date, faecal metabolomic profiling has been 
applied to Crohn’s disease [7], ulcerative colitis [7, 8], liver cirrhosis [9], colorectal cancer (CRC)[10, 
11] and nutritional studies. [12] In addition, faecal analysis provides an insight into the health of the 
bowel microbiome via the analysis of microbial metabolites. [6] Changes in microbial metabolites such 
as secondary bile acids and tetrapyrroles may indicate changes in the population distribution or 
function of the microbiome which, in turn, may signal a disease state or be a potential cause of disease. 
[13, 14] 
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One potential application for faecal metabolomics is to investigate metabolite profiles 
associated with CRC and pre-cancerous polyps in order to aid understanding of disease formation and 
in the early diagnosis of the malignancy. CRC has the third highest morbidity and mortality rate of any 
cancer in the world, with a predicted 135,000 new cases in North America in 2017.[14]  Early diagnosis 
of CRC significantly reduces overall mortality by allowing early intervention. To date, several 
metabolomic studies of CRC have been carried out using tumour tissue samples[15, 16], urine [17]and 
serum from diseased subjects. [18, 19] However the collection of these samples can be invasive and, 
in the case of urine and serum, distant from the tumour site. Faecal samples offer a non-invasive 
alternative which has the advantage of providing a more direct representation of the colonic 
environment and microbial activities in this compartment. Several CRC metabolomic studies of faeces 
have been undertaken, however, for the most part these have utilised nuclear magnetic resonance 
[20] or gas chromatography-mass spectrometry. [11, 21] Any LC-MS analysis of CRC in faeces has 
typically utilised a targeted metabolomic approach, and very few have employed LC-MS for a global 
faecal metabolomic analysis of CRC. [6, 21]  One of the challenges of global metabolomics is to analyse 
as much of the metabolome as possible in the sample, including low abundance compounds alongside 
those present in high concentrations. This is particularly important in studies of CRC where changes in 
the concentrations of signalling metabolites such as secondary bile acids, sex steroids and eicosanoids 
have been associated with onset of the disease. [22-24]  
A recent development in global metabolomics is the introduction of highly sensitive 
nanoflowUHPLC-nanosprayESI-TOFMS (nUHPLC-nESI-TOFMS) methodologies.[25, 26]  nUHPLC 
technology uses columns with 100 µm internal diameters or smaller and flow rates of <1000 nL/min 
resulting in reduced chromatographic dilution and greatly improved ionisation efficiency, enabling low 
and high abundant molecules to be analysed simultaneously in complex matrices. This approach has 
been applied to urine [27, 28], plasma [29, 30] and cell cultures [31]. In these studies, both retention 
time and the mass spectral signal have proven to be highly repeatable and reproducible, while at the 
same time providing a highly sensitive metabolomic analysis. The properties of the nUHPLC-nESI-
HRMS platform enable the analysis and separation of trace level metabolites which would normally 
not be detected using conventional LC-MS methodologies. Furthermore, advances in sample 
preparation methods, which include solid phase extraction (SPE) and pre-concentration, have enabled 
the injection of small sample volumes that are required for nanoscale LC-MS. Previous work has shown 
that hydrophilic/lipophilic balance (HLB) SPE phases are capable of good recoveries of a wide range of 
polar and lipophilic molecules including eicosanoids, bile acids, amino acids, nucleotides, free and 
conjugated steroids and a variety of pharmaceuticals and other xenobiotics, thus indicating that SPE 
is a suitable sample preparation method for metabolomic analysis [29, 32-34]. SPE is also often used 
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to remove salts from faecal water prior to LC-MS analyses for metabolomics [35, 36].  In this study, 
we used the SPE methods based upon our previous SPE nLC-nESI-MS studies where we examined the 
reproducibility, sensitivity and recovery of our sample preparation methods. In these studies we found 
the method to be repeatable and suitable for metabolomics profiling with recoveries of a variety of 
signalling compounds including eicosanoids, free and conjugated sex steroids and bile acids of 
between 60 and 85 % with a repeatability of between 1-13%  [27, 29] .  
 The aim of this study was to assess the potential of nUHPLC-nESI-TOFMS to profile the 
metabolome, including signalling compounds, from faecal extracts from cohort studies. An offline SPE 
sample preparation and nUHPLC-nESI-TOFMS analysis methodology were used and the repeatability 
of the metabolomic analyses was assessed. A metabolomic investigation of a small pilot study 
comprising samples from recently diagnosed CRC, adenomatous polyp and healthy control subjects 
was performed to determine the potential of trace nUHPLC-nESI-TOFMS profiling to detect 
components of the faecal metabolome which could be associated with the onset of CRC. 
 
3.0 Materials and methods 
3.1 Materials 
HPLC grade solvents were purchased from Rathburn Chemicals Ltd (Walkerburn, Scotland, UK) 
and UHPLC grade solvents were purchased from Fisher Scientific UK (Loughborough, UK). Strata X (HLB 
sorbent) 60 mg/3ml SPE 96-well plates were purchased from Phenomenex (Macclesfield, U.K). A mix 
of deuterated compounds were used as internal standards (IS); 17β-estradiol 2,4,16,16-d4 sodium 3-
sulfate (E2-d4-S, >99% D atom), carbamazepine (ring-d10), and diclofenac (phenyl-d4) were purchased 
from Cambridge Isotope Laboratories Inc. (MA, USA). Progesterone-2,2,4,6,6,17R,21,21,21-d9 (P-d9, 
98% D atom) was purchased from CDN isotopes (Quebec, Canada). All other standards and reagent 
chemicals were purchased from Sigma-Aldrich Company Ltd., Dorset, U.K. 
3.2 Sample collection 
In total 7 CRC, 26 healthy and 25 adenomatous polyp faecal samples were collected shortly 
following diagnosis and prior to the initiation of any treatment to ensure any differences detected 
between groups were not attributed to differences in treatment. Samples were collected at the Royal 
Sussex County Hospital, Brighton, UK and the University Hospital Motol, Prague, Czech Republic.  All  
CRC samples came from one hospital (UK) and, with the exception  of one sample, were from male 
subjects. Eligible subjects gave written formal consent for collection and use of their faecal samples. 
Ethical approval for the study was awarded by the South East Coast – Brighton and Sussex NRES 
Committee (REC Reference number 10/H1107/39) and the Ethics Committee for Multi-Centric Clinical 
Trials of the University Hospital Motol (Reference number EK-555/12). 
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No patients were taking antibiotics, probiotics, or pre-biotics at the time of sampling or in the 
3 months preceding sample collection. Patients were matched for age, weight and body mass index 
(BMI) and no significant differences were observed for these parameters between the disease groups 
when analysed according to country of origin or gender status. However, for all subjects the average 
height was significantly shorter (p<0.05) in healthy compared with polyp groups (Table 1).  
3.3 Sample preparation 
Whole stool samples were homogenised and frozen at -80 C. Faecal samples were extracted 
according to a modified methanol extraction method, [34] followed by SPE to remove salts and 
concentrate the sample prior to nUHPLC-nESI-TOFMS analysis. From each faecal sample, a 10 g sub 
sample was taken and homogenised in 20 mL phosphate buffer (PBS) (Ultra Turrax, IKA, Oxford, UK). 
PBS was used as the initial extraction buffer as an aliquot of the samples was also collected for analysis 
of the gut microbiome (to be published). To a 400 mg sub sample of this homogenate, 1.4 mL PBS and 
3.5 µL of 0.1 mg/mL IS mix were added and the sample vortexed then centrifuged at 10,000 g for 10 
minutes. The supernatant was collected and the pellet extracted twice more with methanol (1.4ml). 
From each extract, 50µL was taken and pooled to produce 150 µL (1 part PBS: 2 parts MeOH) of final 
extract for each faecal sample which was diluted with 1.9 mL 0.1% formic acid for HLB SPE extraction. 
Strata X 96-well plates were conditioned with 1 mL methanol and washed with 1 mL water. The 
acidified samples were loaded and the SPE washed with 4 mL of water and the metabolites eluted 
with 0.5 mL methanol and 0.5 mL ethyl acetate. The solvent was removed under vacuum and the 
samples reconstituted in 20 µL 70:30 H2O: MeOH to give a 7.5-fold concentration of the original 150 
µL faecal extract. Samples were injected on nUHPLC-nESI-TOFMS immediately following sample 
preparation. All extraction solvents used were HPLC grade >99% purity. 
3.4 nUHPLC-nESI-TOFMS analysis 
Extracts (0.5 µL, comprising 175 µg equivalent of faeces) were injected onto a Waters 
nanoAcquity UHPLC and separated using a Waters nanoAcquity HSS-T3 (100mm x 100 µm x 1.8 µm, 
100 Å) column. Chromatographic separation was carried out at 700 nL/min using UHPLC grade 
(>99.99% purity) water and acetonitrile as mobile phases A and B respectively, both modified with 
0.01% formic acid. A gradient elution was used: 0 mins 10% B, 4 mins 30% B, 18 mins 50% B, 30 mins 
100% B, 100% B maintained for 10 minutes then equilibrated in initial conditions for a further 15 
minutes. Metabolites were detected in positive and negative nESI modes using a Waters Xevo G2 
TOFMS tuned to a mass resolution of 20,000 and equipped with a nano ESI source using homemade 
pulled fused silica emitters.[26] A sample from each group and a QC sample was also analysed using 
MSE for collisional- induced dissociation with an energy ramp of 10-40 eV to obtain fragment 
information for identification of metabolite structures. 
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3.5 Quality control 
Quality control (QC) samples were produced by pooling 5 µL of each faecal extract from all 
subjects to create a composite mixture. Prior to analysis in both ionisation modes, 5 QC samples were 
injected to condition the nESI source. Injections of the QC sample were carried out every 10 injections 
throughout the analysis to determine instrumental drift in intensity response and retention time data. 
The peak area variability of the QC samples was determined where areas of all peaks present in at 
least 80% of the QC samples were integrated and the % coefficient of variation (CV) of the mean peak 
areas were calculated The % of peaks where the CV of mean peak area was below recommended 
levels of 15% and 30% for metabolomics data was calculated [37, 38]. 
The repeatability of the peak retention time of the nano platform was determined as the % 
CV of the mean retention time for the 100 most abundant peaks (50 in each ionisation mode) in all of 
the samples and QCs analysed. Previous reports suggest that a target % CV should be below 2%.[39]  
3.6 Statistical analysis 
The MS datasets were deisotoped, mass spectral peaks deconvoluted, and the datasets 
binned and normalized to the total spectral area using Waters MarkerLynx software and which is a 
method previously shown to be applicable to nanospray datasets [40]. After exclusion of outliers, the 
variation (CV) of the total spectral area used in normalisation of datasets was 11%. Binned datasets 
were exported to Simca v13.0 software (Umetrics Ltd, Crewe, UK) for multivariate analyses. All data 
were log transformed and Pareto scaled prior to principal components analysis (PCA). Due to the small 
sample sizes in this study, it was not possible to fully validate supervised analyses such as partial least-
squares discriminant analysis or orthogonal partial least-squares discriminant analysis (OPLS-DA). 
However, OPLS-DA models were used to identify metabolites that may potentially drive discrimination 
between sample groups. These metabolites   were detected using an ‘S’ plot of the orthogonal partial 
least-squares discriminant analysis (OPLS-DA) model which is a plot of reliability (correlation) of the 
loading variables versus their covariance (contribution to the model). [41]  
Further statistical analysis was carried out using GraphPad Prism version 6.05 for Windows 
(GraphPad Software, San Diego California USA, www.graphpad.com). The normalised mass intensities 
for discriminatory metabolites highlighted by S-plot analysis were tested for normal distribution 
(D’Agostino’s K squared test) and were then tested for significance at P<0.05 using a one-way ANOVA 
with a Holm-Sidak multiple comparison test to determine p-values. Non-normally distributed data 
were tested using the Kruskal-Wallis with a Dunn’s multiple comparison test to determine p-values. 
Data was also tested for homoscedasticity using the Levenes test. Sample groups with unequal 
variances were analysed using the Brown-Forsythe ANOVA followed by the Games-Howell post hoc 
test to analyse for significant differences between sample groups. Statistically significant metabolites 
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were tested for their predictability using the Receiver-Operator Characteristic (ROC) to plot the false 
positive rate against the true positive rate and the area under the curve was calculated to give the 
probability of a positive result being a true positive. 
Metabolite identities were determined from their accurate mass, isotopic fit, and comparison 
of fragmentation data with in-silico fragmentation from Waters Mass Fragment software, authentic 
standards or with Metlin [42], Human Metabolome Database [43] and MycompoundID [44] databases.  
 
4.0 Results and discussion 
4.1 Repeatability of the metabolomic analyses 
The repeatability of the metabolome peak area was calculated by determining the percentage 
of peaks common to 80% of the QC samples which had a mean peak area CV of < 15% and <30% [37]. 
In this study the mean area of 85.5% (-nESI mode) and 89.5% (+nESI mode) of peaks had a CV <30%, 
whereas 61.6% (-nESI) and 60.7% (+nESI) of peaks gave a mean peak area CV of <15%. This data 
indicated that the repeatability of the analysis of the metabolome peak area was reliable.  
To assess retention time stability, the % CV for the 50 most abundant metabolites in each 
ionisation mode was determined using data from all samples and the QCs analysed. The % CV for 
median retention time was between 0.16 and 1.99%, i.e. between 1.9 and 23.5 seconds, and this is 
within the 2% guideline proposed by Theodoridis et al [39] (see Figure S1). In total 93% of the 100 
peaks investigated had a % CV of <1.5 for retention time stability with 70 of these peaks returning a 
CV <1%. The peaks with the greatest variability tended to be sulphated bile acids or tetrapyrroles 
which were present at very high levels, and typically with broader peaks and varying peak apex 
retention time compared to the other metabolites investigated. The repeatability data in this study 
compare well with previous nUHPLC-nESI-TOFMS analyses of biofluid metabolomes, indicating that 
the nanospray platform was acceptable for profiling faecal extracts.[26, 27, 29]  
4.2 Profiles of metabolites in faecal extracts  
In total, 5387 metabolite signals were detected in +nESI mode and 4851 signals in -nESI mode 
and of these 2256 and 3032 features respectively were putatively annotated using PutMedID [45]. 
This represents a 2-fold increase in metabolite signals that had been reported in previous profiling 
studies of the faecal metabolome using conventional uHPLC-TOF-MS platforms [10, 46].  
Representative base peak intensity (BPI) chromatograms resulting from nUHPLC-nESI-TOFMS 
analyses of extracts of QC samples obtained from a composite of faecal extracts from all study subjects 
are given in Figure 1. Details of structural identification of xenobiotics and metabolites are given in 
Tables S1 and S2. In +ESI mode, highly polar metabolites including amino acids and dipeptides were 
detected in the unretained section of the chromatogram, eluting between 5.2 and 5.8 mins. 
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Tetrapyrrole metabolites, bile acids and lipid metabolites, including sphingosine, pharmaceuticals and 
other xenobiotics also dominated the metabolomic profile. The tetrapyrrole metabolites include 
urobilins and urobilinogens which are the endpoints of haemoglobin and bilirubin metabolism. [9, 12] 
As >90% of the bilirubin is metabolised and excreted in the faeces, then this accounts for the very 
large peak observed for these compounds in the BPI chromatogram. [47] Analyses of selected ion 
chromatograms for the different tetrapyrroles revealed the co-elution of at least four metabolites 
which were identified from high resolution molecular formula and published fragmentation details 
[48, 49] (Figure S2 and Table S2). These were D-Urobilinogen, formed from the deconjugation of 
bilirubin diglucuronide and the downstream metabolites I-urobilinogen, L-urobilin and I-urobilin/D-
urobilinogen.  
Major peaks corresponding to two protease inhibitors, darunavir and ritonavir, were present 
in +nESI BPI profiles. These inhibitors are typically prescribed to patients infected with the human 
immunodeficiency virus (HIV) (Table S1). A total of 20 pharmaceuticals or their metabolites were 
detected in the sample extracts as well as dietary metabolites such as solanidine and piperine. The 
detection of a range of dietary and pharmaceutical metabolites in the metabolome highlight the need 
for detailed knowledge of patients in terms of diet and pharmaceutical intake and the possibility for 
patient stratification for metabolomic studies.  
In -nESI mode the most prevalent class of metabolites detected were free and conjugated bile 
acids (Figure 1). Bile acids have long been thought to play a role in colorectal diseases such as CRC, 
especially the secondary bile acids formed as a result of C7 dehydroxylation by the intestinal 
microflora. [50-52] However, the role of bile acids in the initiation of cancer remains to be clearly 
established, although their signalling properties via interactions with nuclear receptors are a possible 
mechanism [52]. Profiles of bile acids in the QC samples were further investigated using selected ion 
chromatograms to determine the overall coverage of bile acid metabolism (Figure 2, Table S2). A total 
of 32 bile acids were detected of which 18 identities were determined using genuine standards. These 
included the primary bile acids cholic acid, chenodeoxycholic acid, taurocholic acid, 
taurochenodeoxycholic acid, glycocholic acid and glycochenodeoxycholic acid in addition to the major 
secondary bile acids lithocholic acid and deoxycholic acid. The detection of all the major primary and 
secondary bile acids, in addition to the wide array of other less abundant bile acid metabolites is 
promising for studying the role of the metabolome in bowel diseases and the composition of the 
bacterial microbiome responsible for C7 dehydroxylation and deconjugation of taurine or glycine 
groups [53, 54].  
The importance of sex steroids in diseases of the gut is well established, and changes in 
circulating levels of androgens, which act via nuclear receptors, have been linked to CRC [55, 56], 
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Crohn’s disease[57], ulcerative colitis[57] and irritable bowel syndrome.[58] Hence, the ability to 
detect faecal steroids during global metabolomics profiling studies may further help to elucidate their 
function in such conditions and understand the role of the gut microbiome in sex steroid metabolism. 
[59] Nine conjugated androgens were detected in the faecal metabolome, (Figure 3) as well as 
conjugated progestogens, pregnenolone and estrogens (Figure S3). Free steroids tend to be excreted 
via urine, and the only unconjugated steroids detected in faecal extracts were those of progesterone 
and its hydroxylated metabolite, hydroxyprogesterone, together with two other unidentified 
progesterone-like steroids (Figure S4).  
The use of highly sensitive nUHPLC-nESI-TOFMS has enabled the detection of eicosanoids, 
small molecule signalling mediators of inflammation, in untargeted metabolic analyses. [27] 
Eicosanoids such as prostaglandin E2 (PGE2) are inflammatory markers of cancer and non-steroidal 
anti-inflammatory drugs (NSAIDs) are thought to reduce the risk of some cancers, such as CRC, by 
inhibiting the cyclooxygenase enzymes responsible for eicosanoid production. [60] In this study, PGE2 
was detected in the faecal metabolome alongside a number of other unidentified eicosanoid peaks 
(Figure S5).  Our studies reveal that low abundance signalling compounds such as prostaglandins, 
progesterones, and sex steroids were detected during profiling of the faecal metabolome using the 
nanospray platform. These metabolites are normally present at sub nM concentrations in blood or 
faeces [61] and were not detected in previous conventional LC-MS profiling studies of the faecal 
metabolome [62, 63] and have only previously been detected in faecal extracts using targeted LC-MS 
analyses [64].  Low abundance signalling metabolites in the faecal metabolome would not have been 
detected using other analytical platforms such as NMR. However it should be recognised that no one 
analytical platform can analyse the full complement of the metabolome., and that semi- volatile  or 
polar metabolites present in faecal extracts are not retained by LC columns and are usually analysed 
by GC-MS [36].   
 4.3 nUHPLC-nESI-TOFMS profiling of faecal extracts from disease groups 
A pilot study comprising samples of faecal extracts from 7 CRC, 25 polyp and 26 healthy 
patient groups were profiled by nUHPLC-nESI-TOFMS in both +nESI and -nESI modes and the datasets 
analysed by multivariate modelling. Principal component score plots were constructed for the 
datasets (Figures S6 and S7). Tight clustering of the QC samples in both ionisation modes further 
indicated that the metabolomic analyses were highly repeatable. However, using unsupervised 
analyses no discrimination between sample sources (Prague versus UK) or between disease groups 
was apparent, possibly due to the high amount of inter-individual variation in the faecal metabolome. 
Due to the small sample groups in this work it was not possible to fully validate supervised analysis 
such as PLS-DA or OPLS-DA, however OPLS-DA models were used to identify metabolites that may 
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potentially drive discrimination between sample groups. Analysis of the S-plots of the loading variables 
of models tentatively revealed ten metabolites driving discrimination between the sample groups. 
Further univariate and ROC analysis of these metabolites highlighted in the S-plots were used to 
determine significant differences in concentrations between sample groups (Table 2). Box plots of 
these putative discriminating metabolites were also constructed (Supplementary Figure S8), and 
demonstrate the significant biological variation in the faecal metabolome. Discriminating metabolites 
included a putative porphyrin metabolite which was detected at >40-fold higher concentrations in the 
CRC group compared with healthy or polyp groups. Haem metabolites are known to be markers of 
CRC disease [10] and the identity of this metabolite warrants further investigation as all of the patients 
in this study were referred for colonoscopy due to a positive result in a faecal occult blood test of 
which only seven were diagnosed with CRC. In addition, concentrations of a potential cholesterol 
oxidation product, two other unidentified nitrogen containing lipids, a phospholipid and a phytyl 
phosphate type metabolite were significantly higher in CRC compared to healthy and polyp groups.  
In a recent metabolomics study, both 7 and 12-ketodeoxycholic acid have been observed to 
be up-regulated in CRC tissue[15]. Similarly in our pilot study, concentrations of two unidentified keto 
bile acid structures were significantly higher in the CRC patient group. A comparison with the retention 
time of standards revealed that these secondary bile acids were not 7 and 12-ketodeoxycholic acids 
or other known keto bile acids associated with the gut metabolome (i.e. 3-oxocholic acid, 3,7 
dihydroxy-12-oxocholic acid or 7-ketolithocholic acid). The identity and role of low abundant keto bile 
acids in bowel diseases warrants further study. A further analysis of the peak areas of the major bile 
acids detected in our study was undertaken and revealed that there were no significant differences in 
the levels of the primary bile acids and other secondary bile acids between CRC and either the healthy 
or polyp sample groups (data not shown).  
  A 3.1 fold increase in abundance of trace levels of a dinor prostaglandin metabolite was 
observed in the CRC group which may be a reflection of inflammatory processes. PGE2 and 
thromboxane B2 have been found to be increased in tumours from CRC patients.[60, 65, 66] It is 
possible that a larger study with more CRC samples may uncover additional eicosanoids that have 
become disrupted as a result of cancer and polyp development. This finding warrants further 
investigation due to the potential benefits of NSAID consumption in reducing CRC and polyp incidence.  
 This metabolomics study also revealed that concentrations of an unidentified 
androgen sulfate metabolite were significantly reduced in samples from CRC subjects compared to 
the healthy group. Reduced androgen levels have previously been reported in male CRC patients 
possibly as a result of reduced circulating levels of the sex hormone binding globulin in these 
subjects.[55, 56]  
AC
CE
PT
ED
 M
AN
US
CR
IPT
 11 
 
The 10 metabolites associated with the CRC group were re-analysed by univariate statistics 
following the exclusion of all patients from Prague and female subjects to eliminate and bias 
introduced by hospital and gender. Concentrations of all the metabolites, with the exception of the 
androgen sulfate, were still significantly different between healthy and CRC groups. However, 
concentrations of metabolites of m/z 381.3117, 443.2875 and the octadecyl lysophosphatidic acid like 
metabolite were no longer significant between CRC and polyp groups.  
The discriminating metabolites detected in this pilot study require validation in a larger follow-
up study, with tight dietary controls to remove inter-individual variability.  Furthermore, although 
some of the metabolites ( e.g. the prostaglandin and androgen sulfate) that were detected in this pilot 
study were not obviously dietary in source,  it is possible diet may influence the CRC-associated 
metabolome and thus a diet-controlled study would further validate any future findings.    
 
5.0 Conclusions 
This study was the first to incorporate nanoscale UHPLC-TOFMS in a faecal metabolomic study 
and, to our knowledge, the first to use this technology to provide an overview of selected low and 
high abundance compounds represented in the faecal metabolome. Metabolite profiling of faecal 
extracts revealed the presence of trace levels of eicosanoid and sex steroid signalling compounds 
alongside compounds of high abundance including xenobiotics, tetrapyrrole and the major bile acid 
metabolites. Profiling of faecal extracts using the nUHPLC-nESI-TOFMS platform was highly 
repeatable.  A small pilot study revealed that signalling metabolites as well other key metabolic 
pathways are potentially implicated in the CRC sample group. However, due to the small scale of this 
work and the variability associated with dietary influences,  more studies are required with larger 
sample sets to improve statistical power to validate and uncover discriminating metabolites for CRC 
disease. In future larger studies it would also be prudent to standardise the patient’s diet prior to 
sampling in order to control for variation in metabolite profiles due to food. In addition, normalising 
datasets to the water content of the sample may also improve the analytical method [6].  
Nevertheless, our study reveals the potential of the nanoscale platform to be used in larger scale 
studies to identify the role of the metabolome in the onset of colorectal diseases.  
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Figure captions. 
Figure 1: Base Peak Intensity chromatograms of faecal QC samples analysed in +nESI and -nESI 
modes. Equivalent of 175 µg wet weight of faeces injected onto the nUHPLC-nESI-TOFMS. -Mass 
spectrum data of the identified xenobiotics and metabolites are given in Supplementary Tables S1 and 
S2. 
Figure 2: Major primary and secondary bile acids present in the faecal metabolome (- nESI mode). 
Selected ion chromatograms of all primary and secondary bile acids present in the faecal 
metabolomes, the latter being formed by the bowel microbiome via C7 hydroxylation of amine 
conjugates. All peaks detected using a mass window of 5PPM. Primary and secondary bile acids 
confirmed by comparison of retention time and fragmentation patterns with genuine standards 
(Supplementary Table S2). 1-4 correspond to the structure C24H40O5 and isomers of cholic acid, 5 is 
glycohydodeoxycholic acid confirmed by a genuine standard. Peak 6 corresponds to the molecular 
formula C24H40O4 a glycine conjugated bile acid. Peaks 7 and 8 are C24H40O4  isomers of deoxycholic 
acid. Peaks 9 and 10 correspond to ursodeoxycholic acid and hyodeoxycholic acid, respectively, and 
peak 11 to allolithocholic acid. 
Figure 3: Faecal conjugated androgens detected in negative nESI mode in a pooled quality control 
sample. Overlaid selected ion chromatograms of faecal conjugated androgens detected with a mass 
window of 5PPM, 1). Here the 383.1527/C19H28O6S peaks are dihydroxyandrosterone sulfate like 
metabolites, 2) Androsterone and dihydrotestosterone sulfate like with the mass/formula 369.1738 
C19H30O5S, 3) The 367.1577 peak at 13.9 min corresponds to dihydroepiandrosterone as confirmed 
by a pure standard, 4) Androsterone and dihydrotestosterone glucuronide structures with the mass 
M-H 465.2485 and molecular formula C25H38O8. All peaks identified as conjugated androgens 
based upon accurate mass measurement and in the case of sulphates HSO3 and HSO4 fragments 
(Supplementary Table S2).  
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Figure 1: Base Peak Intensity chromatograms of faecal QC samples analysed in +nESI and -nESI 
modes 
Equivalent of 175 µg wet weight of faeces injected onto the nUHPLC-nESI-TOFMS. -Mass spectrum 
data of the identified xenobiotics and metabolites are given in Supplementary Tables S1 and S2. 
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Figure 2: Major primary and secondary bile acids present in the faecal metabolome (- nESI mode) 
Selected ion chromatograms of all primary and secondary bile acids present in the faecal 
metabolomes, the latter being formed by the bowel microbiome via C7 hydroxylation of amine 
conjugates. All peaks detected using a mass window of 5PPM. Primary and secondary bile acids 
confirmed by comparison of retention time and fragmentation patterns with genuine standards 
(Supplementary Table S2). 1-4 correspond to the structure C24H40O5 and isomers of cholic acid, 5 is 
glycohydodeoxycholic acid confirmed by a genuine standard. Peak 6 corresponds to the molecular 
formula C24H40O4 a glycine conjugated bile acid. Peaks 7 and 8 are C24H40O4  isomers of deoxycholic 
acid. Peaks 9 and 10 correspond to ursodeoxycholic acid and hyodeoxycholic acid, respectively, and 
peak 11 to allolithocholic acid. 
 
 
AC
CE
PT
ED
MA
NU
SC
RI
PT
 19 
 
 
Figure 3: Faecal conjugated androgens detected in negative nESI mode in a pooled quality control 
sample 
Overlaid selected ion chromatograms of faecal conjugated androgens detected with a mass window 
of 5PPM, 1). Here the 383.1527/C19H28O6S peaks are dihydroxyandrosterone sulfate like 
metabolites, 2) Androsterone and dihydrotestosterone sulfate like with the mass/formula 369.1738 
C19H30O5S, 3) The 367.1577 peak at 13.9 min corresponds to dihydroepiandrosterone as confirmed 
by a pure standard, 4) Androsterone and dihydrotestosterone glucuronide structures with the mass 
M-H 465.2485 and molecular formula C25H38O8. All peaks identified as conjugated androgens 
based upon accurate mass measurement and in the case of sulphates HSO3 and HSO4 fragments 
(Supplementary Table S2).  
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Table 1: Patient sex, age and anthropometric data according to country of origin (mean ± standard 
deviation). 
Sample group Numbers 
of male 
subjects 
Number 
of female 
subjects 
Age (yrs) Height (m) Weight (kg) BMI (kg/m2) 
Healthy -all subjects 13 13 60.3±12.0 1.69±0.12* 77.0±17.0 27.1±5.7 
Healthy -Prague only 4 2 60.5±10.9 1.71±0.11 87.3± 23.7 29.7±6.3 
Healthy -UK only 9 11 61.0± 13.0 1.68±0.11 73.3± 13.5 26.1±4.5 
Healthy -all males  13  61.69±9.8 1.76±0.076 87.1±13.8 28.1±4.6 
Healthy- all females    13 60.2±15.1 1.60±0.085 66.1±13.0 25.7±5.4 
Polyp- all subjects 19 6 63.5±11.2 1.76±0.09 84.7±15.9 27.4±4.9 
Polyp -Prague only 11 2 61.1±10.0 1.76±0.09 87.3± 17.6 28.2±5.8 
Polyp-UK only 8 4 66.2± 12.1 1.76±0.09 81.5± 13.8 26.4±3.6 
Polyp- all males 19  65.1±10.9 1.78±0.077 90.1±13.1 28.4±4.6 
Polyp- all females  6 58.8±11.4 1.68±0.087 67.8±11.4 24.2±4.6 
CRC- all subjects (UK) 6 1 64.4±7.2 1.76±0.04 81.6±26.0 26.0±7.4 
CRC-all males 6  65.3±7.5 1.77±0.037 87.9±21.9 27.8±6.1 
CRC- female   1 59 1.70 43.7 15.1 
*Height of healthy patients (all subjects) were significantly lower compared to the polyp but not CRC 
all subject group as assessed by the Holm-Sidak multiple comparison test. No other differences were 
observed for comparisons between healthy, polyp or CRC classes when subjects were grouped either 
according to country (both sexes together ) or gender (both countries together).   
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Table 2: Putative identities of significantly (p<0.05) discriminating metabolites between CRC, polyp and healthy samples. 
Measured 
Mass 
(relative 
intensity 
after CID) 
Formula PPM RT Fragments 
(relative 
intensity 
after CID) 
Identity Statistical 
measure 
CRC vs Healthy CRC vs Polyp Healthy vs Polyp 
Discriminating metabolite detected in positive nESI mode     
381.3117 
(73) 
C22H40N2O3 0.0 17.25 
363.3026 
(100), 
359.2176 
(30) 
Unknown 
p-value 
Fold change 
AUC 
p=0.05 
5.6x higher in CRC 
0.8489 
p=0.05 
5.5x higher in CRC 
0.8333 
ns 
379.2991 
(59) 
C27H38O 2.6 15.19 
+361.2863 
(100), 
+275.1763 
(3), 
+265.1628 
(72) 
Cholesterol 
oxidation product 
p-value 
Fold change 
AUC 
p=0.0014 
4.7x higher in CRC 
0.9231 
p=0.0032 
4.6x higher in CRC 
0.9226 
ns 
443.2875 C19H43N2O7P 2.5 20.39 nd Unknown 
p-value 
Fold change 
p=0.0026 
3.0x higher in CRC 
p=0.0045 
1.8x higher in CRC 
ns 
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AUC 0.8462 0.8214 
689.3567 C38H48N4O8 2.5 8.37 nd 
Porphyrin 
metabolite (+C2H4) 
p-value 
Fold change 
AUC 
p=0.0002 
42.9x higher in CRC 
0.8297 
p=0.0001 
55.6x higher in CRC 
0.8333 
ns 
Discriminating metabolite detected in negative nESI mode   
423.2879 
(100) 
C21H45O6P 0.7 15.1 
+405.2811, 
(22) 
Octadecyl 
lysophosphatidic 
Acid like metabolite 
p-value 
Fold change 
AUC 
p=0.0006 
8.8x higher in CRC 
0.9396 
p=0.0029 
12.7x higher in CRC 
0.9345 
ns 
375.2662 
(100) 
C20H41O4P 0.5 14.4 
96.9601  
(4) 
79.9579 
(1) 
Phytyl phosphate 
p-value 
Fold change 
AUC 
p=0.040 
4.6x higher in CRC 
0.8736 
p=0.042 
4.8x higher in CRC 
0.8512 
ns 
405.2647 
(100) 
C24H38O5 0.2 13.3 
+165.0572, 
(4) 
+145.0680, 
(2) 
+143.0469 
Keto bile acid 
structure 
p-value 
Fold change 
AUC 
p=0.0063 
2.4x higher in CRC 
0.8571 
ns ns 
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(2) 
389.2694 
(100) 
C24H38O4 
0.5 
 
21.7 
+371.2618, 
(1) 
+343.2656, 
(1) 
+325.2545 
(1) 
Keto bile acid 
structure 
p-value 
Fold change 
AUC 
p=0.0538 (ns) 
1.8x higher in CRC 
0.7747 
ns 
p=0.0123 
1.6 higher in polyp 
0.7420 
325.2012 
(63) 
C18H30O5 0.9 24.7 
307.187, 
(100) 
289.195 
(55) 
Dinor prostaglandin 
p-value 
fold change 
AUC 
p=0.0133 
2.6x higher in CRC 
0.8187 
p=0.0035 
3.1 higher in CRC 
0.9048 
 
ns 
 
369.1737 
(100) 
C19H30O5S 0.3 11.7 
+275.1964 
(1) 
96.9603 
(3) 
78.9600 
(1) 
Androgen sulfate 
p-value 
Fold change 
AUC 
p=0.0464 
5.6x higher in healthy 
0.8159 
ns ns AC
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AUC values refer to receiver operator characteristic area under the curve as a measure of the false discovery rate, values greater than 0.7 are typically 
highly reliable markers, the closer to 1 the greater the predictability of the metabolite marker. Fragments denoted with + represent observed fragments 
which agree with predicted fragments generated using Waters Mass Fragment software. Numbers in brackets refer to relative percentage intensity for 
fragment and parent ions after collision-induced dissociation, CID. 
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